



UTAH STATE SENATE

UTAH STATE CAPITOL COMPLEX • 320 STATE CAPITOL
P.O. BOX 145115 • SALT LAKE CITY, UTAH 84114-5115 • (801) 538-1035

SB 190 Medical Cannabis Act Amendments

Sen. Vickers, Rep. Ferry

- Clarifies the distinction between allowable hemp products and medical cannabis products based on tetrahydrocannabinol (THC) and THC analog concentration (Lines 109-11, 167-83, 777-78)
- Requires certain retailers marketing a hemp or cannabinoid product to include a statement that the product is not cannabis or medical cannabis (Lines 200-03)
- Requires the identification of any cannabinoids above a certain quantity in a cannabis product (Lines 216-18)
- Identifies an unlawful act of distributing, selling, or marketing an industrial hemp product that contains a certain amount of THC or a THC analog (Lines 236-40)
- Allows the Utah Department of Agriculture and Food (UDAF) to partner with research universities to provide cannabis testing laboratories (Lines 543-56)
- Grants rulemaking authority to UDAF to establish performance standards for licensed independent cannabis testing laboratories (Lines 563-68)
- Provides that certain licenses are non-transferable, and new owners of a licensed business are subject to a modified application process for a new license (Lines 569-82, 1827-44, 2419-34)
- Prohibits the introduction of industrial hemp waste from outside the state into the medical cannabis production stream (Lines 617-632)
- Provides rulemaking authority to UDAF to further define standards regarding labels, packaging, and product forms that may appeal to children (Lines 643-45, 703-04, 725-25)
- Amends product labeling requirements (Lines 654, 692-93, 2133-48)
- Clarifies that a sugar coating on certain cannabis product is not prohibited under certain circumstances (Lines 726-28)

SB 195 Medical Cannabis Access Amendments

Sen. Escamilla, Rep. Ward

- Requires a hospice program to provide at least one qualified medical provider (Lines 199-201)
- Renames the Cannabinoid Product Board as the Cannabis Research Review Board (Lines 71, 209, 220, 260, 652)
- Requires the four physician members of the Cannabis Research Review Board to be qualified medical providers (Lines 226)
- Adds acute pain for which a medical professional may generally prescribe opioids as a qualifying condition for a limited supply of medical cannabis (Lines 539-41, 1021-23)
- Amends provisions related to advertising regarding medical cannabis (Lines 778-85, 831-66, 1316-24, 1328-86, 1491-97)
- Requires a recommending medical provider to consider a patient's history of substance use or opioid use disorder before recommending medical cannabis (Lines 1000-01)
- Amends provisions regarding the process to renew a medical cannabis card (Lines 1030-37)
- Allows a designated caregiver facility to receive medical cannabis shipments on behalf of a resident patient (Lines 1149-51, 1507-08, 1512-13)
- Allows a student's lawful dosage of medical cannabis on school grounds (Lines 1159-61)
- Codifies a rule regarding the names and logos of medical cannabis pharmacies (Lines 831-66)
- Clarifies the enforcement authority of the Department of Health in relation to licensed medical cannabis couriers (Lines 1552-57)
- Requires certain individuals overseeing certain higher education medical training to be qualified medical providers (Lines 1596-98)

(Continued on back)